MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Quidel Corp

Fechado

13.88 -2.05

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.83

Máximo

14.29

Indicadores-chave

By Trading Economics

Rendimento

602M

-131M

Vendas

24M

724M

Margem de lucro

-18.062

Funcionários

6,500

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+94.35% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-193M

1B

Abertura anterior

15.93

Fecho anterior

13.88

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de abr. de 2026, 17:04 UTC

Grandes Movimentos do Mercado

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 de abr. de 2026, 00:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Big Yachts, Big Bucks -- Barrons.com

10 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 de abr. de 2026, 21:01 UTC

Ganhos

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

10 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 20:31 UTC

Conversa de Mercado

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 de abr. de 2026, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

10 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de abr. de 2026, 19:08 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 de abr. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 de abr. de 2026, 18:25 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Finish With Weekly Gains -- Market Talk

10 de abr. de 2026, 18:05 UTC

Conversa de Mercado

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 de abr. de 2026, 17:31 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 de abr. de 2026, 17:26 UTC

Ganhos

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 de abr. de 2026, 17:10 UTC

Conversa de Mercado

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 de abr. de 2026, 17:00 UTC

Notícias Principais

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 de abr. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de abr. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

10 de abr. de 2026, 16:12 UTC

Ganhos

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 de abr. de 2026, 16:11 UTC

Ganhos

Partners Group: Traditional Programs Contributed $3.3B

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 de abr. de 2026, 16:10 UTC

Ganhos

Partners Group 1Q New Client Demand $8.3B

10 de abr. de 2026, 16:09 UTC

Ganhos

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 de abr. de 2026, 15:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Plenitude Completes Acquisition of Acea Energia

10 de abr. de 2026, 15:38 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

94.35% parte superior

Previsão para 12 meses

Média 27.5 USD  94.35%

Máximo 38 USD

Mínimo 17 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

Resultado Operacional

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat